Amid the FDA chaos there is a new program that cuts review times from 10-12 months to one to two months some companies focused on addressing unmet public health needs, boosting domestic production, or delivering innovative cures. That sounds like us.

Plus, user fee programs are facing uncertainty due to recent FDA cuts and upcoming reauthorization negotiations. This needed to be restructured for sure.